Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-β749), a long-acting...
Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts(1) (non-GAAP) of...
Royalty Pharma purchases a portion of royalties on Rocheβs Evrysdi for $1.0 billion upfrontPTC Therapeutics has...
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has...
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the...
β’ Proceeds to support continued development and commercialization of Endocrine Rare Disease products and...
- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and...
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.